Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSI) EBT Margin (2022 - 2026)

TriSalus Life Sciences has reported EBT Margin over the past 5 years, most recently at 17.34% for Q1 2026.

  • For Q1 2026, EBT Margin rose 13046.0% year-over-year to 17.34%; the TTM value through Mar 2026 reached 60.84%, up 2381.0%, while the annual FY2025 figure was 86.86%, 1520.0% up from the prior year.
  • EBT Margin for Q1 2026 was 17.34% at TriSalus Life Sciences, up from 73.86% in the prior quarter.
  • Over five years, EBT Margin peaked at 17.34% in Q1 2026 and troughed at 698.57% in Q4 2022.
  • A 5-year average of 192.7% and a median of 113.12% in 2025 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: soared 50056bps in 2024 and later crashed -6074bps in 2025.
  • Year by year, EBT Margin stood at 698.57% in 2022, then rose by 11bps to 622.93% in 2023, then surged by 80bps to 122.37% in 2024, then skyrocketed by 40bps to 73.86% in 2025, then soared by 123bps to 17.34% in 2026.
  • Business Quant data shows EBT Margin for TLSI at 17.34% in Q1 2026, 73.86% in Q4 2025, and 93.43% in Q3 2025.